Results of Cox univariate and multivariate analysis for TMA
| Value . | N . | No. of TMA . | Univariate hazard rate ratio (95% CI) . | Univariate P . | Multivariate hazard rate ratio (95% CI) . | Multivariate P . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| Less than 48 | 44 | 9 | Baseline | * | ||
| 48 or older | 41 | 7 | 0.8 (0.3-2.16) | 0.66 | ||
| Patient/donor sex match | ||||||
| Others | 64 | 12 | Baseline | * | ||
| Male patient/female donor | 21 | 4 | 0.99 (0.32-3.07) | 0.99 | ||
| Disease risk | ||||||
| Low | 47 | 12 | Baseline | Baseline | 0.18 | |
| High | 38 | 4 | 0.39 (0.13-1.21) | 0.10 | 0.46 (0.14-1.44) | |
| Conditioning regimen | ||||||
| Flu/Mel | 46 | 3 | Baseline | Baseline | 0.03 | |
| TBI/VP16 and Bu/Cy | 39 | 13 | 5.61 (1.6-19.68) | 0.007 | 4.03 (1.12-14.42) | |
| Patient CMV serology | ||||||
| Negative | 21 | 3 | Baseline | * | ||
| Positive | 64 | 13 | 1.47 (0.42-5.17) | 0.55 | ||
| CD34 cell dose | ||||||
| Less than 5.1 | 44 | 8 | Baseline | * | ||
| 5.1 or more | 41 | 8 | 1.03 (0.39-2.75) | 0.95 | ||
| Acute GVHD | ||||||
| Grade 0 to I | 51 | 4 | Baseline | Baseline | 0.02 | |
| Grade II to IV | 34 | 12 | 5.00 (1.61-12.53) | 0.005 | 3.89 (1.24-12.28) | |
| Tacrolimus† | ||||||
| Less than 25th (< 7.8) | 22 | 2 | Baseline | * | ||
| 25th to 50th (7.8-9.2) | 20 | 4 | 2.20 (0.40, 12.0) | 0.36 | ||
| 50th to 75th (9.3-10.3) | 21 | 4 | 1.86 (0.34, 10.15) | 0.47 | ||
| More than 75th (> 10.3) | 21 | 6 | 3.10 (0.63, 15.38) | 0.17 | ||
| Sirolimus† | ||||||
| Less than 25th (< 5.9) | 22 | 3 | Baseline | * | ||
| 25th to 50th (5.9-7.2) | 23 | 4 | 1.29 (0.29, 5.76) | 0.74 | ||
| 50th to 75th (7.3-8.9) | 19 | 4 | 1.56 (0.35, 6.95) | 0.56 | ||
| More than 75th (> 8.9) | 21 | 5 | 1.82 (0.43, 7.61) | 0.41 |
| Value . | N . | No. of TMA . | Univariate hazard rate ratio (95% CI) . | Univariate P . | Multivariate hazard rate ratio (95% CI) . | Multivariate P . |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| Less than 48 | 44 | 9 | Baseline | * | ||
| 48 or older | 41 | 7 | 0.8 (0.3-2.16) | 0.66 | ||
| Patient/donor sex match | ||||||
| Others | 64 | 12 | Baseline | * | ||
| Male patient/female donor | 21 | 4 | 0.99 (0.32-3.07) | 0.99 | ||
| Disease risk | ||||||
| Low | 47 | 12 | Baseline | Baseline | 0.18 | |
| High | 38 | 4 | 0.39 (0.13-1.21) | 0.10 | 0.46 (0.14-1.44) | |
| Conditioning regimen | ||||||
| Flu/Mel | 46 | 3 | Baseline | Baseline | 0.03 | |
| TBI/VP16 and Bu/Cy | 39 | 13 | 5.61 (1.6-19.68) | 0.007 | 4.03 (1.12-14.42) | |
| Patient CMV serology | ||||||
| Negative | 21 | 3 | Baseline | * | ||
| Positive | 64 | 13 | 1.47 (0.42-5.17) | 0.55 | ||
| CD34 cell dose | ||||||
| Less than 5.1 | 44 | 8 | Baseline | * | ||
| 5.1 or more | 41 | 8 | 1.03 (0.39-2.75) | 0.95 | ||
| Acute GVHD | ||||||
| Grade 0 to I | 51 | 4 | Baseline | Baseline | 0.02 | |
| Grade II to IV | 34 | 12 | 5.00 (1.61-12.53) | 0.005 | 3.89 (1.24-12.28) | |
| Tacrolimus† | ||||||
| Less than 25th (< 7.8) | 22 | 2 | Baseline | * | ||
| 25th to 50th (7.8-9.2) | 20 | 4 | 2.20 (0.40, 12.0) | 0.36 | ||
| 50th to 75th (9.3-10.3) | 21 | 4 | 1.86 (0.34, 10.15) | 0.47 | ||
| More than 75th (> 10.3) | 21 | 6 | 3.10 (0.63, 15.38) | 0.17 | ||
| Sirolimus† | ||||||
| Less than 25th (< 5.9) | 22 | 3 | Baseline | * | ||
| 25th to 50th (5.9-7.2) | 23 | 4 | 1.29 (0.29, 5.76) | 0.74 | ||
| 50th to 75th (7.3-8.9) | 19 | 4 | 1.56 (0.35, 6.95) | 0.56 | ||
| More than 75th (> 8.9) | 21 | 5 | 1.82 (0.43, 7.61) | 0.41 |